Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial (Slow-SPEED)

Slow-SPEED-United Kingdom: A Double-Blind Randomised Feasibility Trial of a Remote Gamified Physical Activity Programme in Adults With Hyposmia.

Slow-SPEED UK is an 18-month randomised, double-blind feasibility trial evaluating the delivery, adherence, and acceptability of a digitally supported physical activity programme in community-dwelling adults aged 40 and over with objectively confirmed hyposmia (reduced sense of smell) and low baseline physical activity.

Participants are randomly assigned 1:1 to either a full-dose activity-support programme (targeting a 100% increase in daily step count) or a very low-dose active control (targeting a 10% increase). Both arms are delivered via a smartphone application linked to a wearable activity monitor (Fitbit Charge 6), with personalised weekly goals expressed as relative percentages to maintain blinding. The study is not designed to test clinical efficacy.

Study Overview

• Status: Not yet recruiting
• Conditions: Anosmia; Hyposmia; Olfactory Dysfunction
• Intervention / Treatment: Other: Slow-SPEED app

Detailed Description

Slow-SPEED UK is an 18-month, randomised, double-blind, parallel-group feasibility trial evaluating the feasibility, acceptability, and safety of a digitally supported physical activity programme in community-dwelling adults aged 40 and over with objectively confirmed hyposmia (reduced sense of smell) and low baseline physical activity. The study is not designed or powered to assess clinical efficacy or disease outcomes.

Participants are identified through two routes: the PREDICT-PD research platform at Queen Mary University of London, and the Smell and Taste Clinic at James Paget University Hospital NHS Foundation Trust. Potential participants undergo telephone pre-screening followed by confirmatory olfactory testing using the 40-item University of Pennsylvania Smell Identification Test (UPSIT). Those scoring at or below the 15th percentile for age and sex are classified as hyposmic. Eligible individuals then enter a 4-week run-in period during which habitual daily step count is measured using a Fitbit Charge 6. Only those averaging fewer than 7,000 steps per day over at least 21 valid days proceed to randomisation. If recruitment falls below 70% of target after the first two months, and subject to Sponsor approval and REC amendment, the eligibility threshold may be broadened to fewer than 10,000 steps per day.

Eligible participants are randomly assigned 1:1 to one of two arms using sequentially numbered opaque sealed envelopes, stratified by age, sex, baseline activity level, and severity of smell loss. Double-blinding is maintained by presenting all activity goals within the smartphone application as relative percentage targets rather than absolute step values, ensuring neither participants nor investigators are aware of group allocation during the study period.

Both arms use the Slow-SPEED smartphone application integrated with the Fitbit Charge 6 wearable activity tracker. The intervention arm targets a progressive increase in daily step count up to 100% above individual baseline, with weekly goals increasing by 5% increments. The active control arm targets a 10% increase above baseline, with weekly goals increasing by 0.5% increments. Both arms use the same application structure, automated feedback, goal progression algorithm, and motivational features, including gamification, visualised progress, and optional non-directive motivational prompts. All participants also complete assessments using the Roche Mobile Application V2 (remote motor tasks performed every 6 weeks throughout the study period) and wear an Axivity AX6 accelerometer for 7-day bursts at baseline, 9 months, and 18 months.

Assessments are conducted at three time points: baseline (in-person), 9 months (remote), and 18 months (in-person). Baseline and 18-month in-person visits include olfactory testing (UPSIT), blood pressure measurement using standard sphygmomanometry, clinical motor assessment (MDS-UPDRS Part III), digital motor tasks (BRAIN test, Digital Finger Tapping, Manus Neurodynamica digital pen, NeuroClues eye-tracking), and a structured battery of questionnaires covering physical activity (LAPAQ), mood and anxiety (HADS), sleep quality (PSQI), quality of life, autonomic symptoms (SCOPA-AUT), and cognitive screening (MoCA). The 9-month remote assessment includes questionnaires and remote digital task completion. Physical activity is measured continuously throughout the study period via the Fitbit Charge 6.

The primary endpoint is the change in average daily step count from baseline (weeks 0-4) to the final four weeks of the 18-month study period, analysed descriptively as a measure of engagement and sustainability. Secondary endpoints include change in moderate-to-vigorous physical activity (MVPA), wearable-derived digital mobility and gait measures, motor and non-motor assessments, and participant-reported outcomes including health-related quality of life and usability of the digital tools.

The primary objective is to evaluate feasibility, defined by recruitment rate, retention, adherence to the intervention, engagement with digital tools, completeness of outcome data, and safety over 18 months. Secondary objectives are descriptive and exploratory. All analyses follow the intention-to-treat principle and emphasise estimation with 95% confidence intervals rather than hypothesis testing. Results will be used to inform the design and operational parameters of a future definitive trial.

• Study Type: Interventional
• Enrollment (Estimated): 110
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Viktoria Azoidou, PhD, MSc, BSc; Phone Number: 0207 882 3850; Email: v.azoidou@qmul.ac.uk
• Study Contact Backup: Name: Alastair J Noyce, BMedSci, MBBS, MSc, MRCP, PhD; Phone Number: 0207 882 3850; Email: a.noyce@qmul.ac.uk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion criteria

• Age ≥ 40 years
• Objective hyposmia, defined as scoring below the 15th percentile (adjusted for age/sex) on UPSIT
• Ability and willingness to provide written informed consent
• Proficiency in written and spoken English sufficient to complete study procedures.
• Willingness and ability to attend baseline (in-person), 9-month (remote), and 18-month (in-person) assessments.
• Access to telephone or internet for interim communication. Specifically, in possession of a suitable smartphone (screen size minimum 4.6 inch; Android version 9 or iOS version 15 or newer).
• Physical activity threshold: During the 4-week eligibility run-in, the mean daily step count must be <7,000 steps/day, calculated over ≥21 valid days (a valid day = ≥10 hours wear time or ≥1,000 steps). If recruitment after the first 2 months is <60-70% of target, and subject to TSC/Sponsor approval and REC amendment, eligibility may be broadened to <10,000 steps/day (i.e. participants averaging 7,000-9,999 steps/day become eligible).

Exclusion criteria

• Clinical diagnosis of PD, dementia, or other neurodegenerative conditions
• Severe or unstable medical or psychiatric illness likely to impair participation
• Use of agents known to alter olfaction (e.g. intranasal zinc, chronic corticosteroids)
• Current enrolment in an interventional study within the past 3 months (standard research retention guidance).
• Inability to complete study procedures in English, per investigator assessment
• Unable to give consent
• Participants not living independently in the community. Participants in nursing homes, hospitalised persons on in a non-institutionalised setting are excluded.
• Subject's personal smartphone is Fitbit-incompatible i.e. Huawei P8 Lite; Huawei P9 Lite; Xiaomi Mi 6; Huawei P20 Lite
• Activity level above threshold during eligibility run-in: mean daily step count ≥7,000 steps/day (or ≥10,000 steps/day if the broadened threshold is activated).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 100% exercise increase; Arm: Full-Dose Exercise Group Participants in this arm will be asked to increase their average daily step count by 100% compared with baseline. Using a Fitbit smartwatch and the Slow-SPEED smartphone app, they will receive personalised step goals, real-time feedback, and gamified challenges to encourage gradual and sustained increases in physical activity. The programme is delivered remotely and unsupervised over 18 months, with progress monitored continuously through the wearable device.	Other: Slow-SPEED app; Gamified motivational smartphone app
Active Comparator: 10% exercise increase; Arm: Low-Dose Control Group Participants in this arm will be asked to increase their average daily step count by 10% compared with baseline. Like the intervention group, they will use a Fitbit smartwatch and the Slow-SPEED smartphone app, receiving similar gamified feedback and motivational tools. The lower step target provides an active control condition while maintaining blinding. The programme is delivered remotely and unsupervised over 18 months, with continuous monitoring via the wearable device.	Other: Slow-SPEED app; Gamified motivational smartphone app

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Average Daily Step Count	Change in average daily step count from baseline (weeks 0-4) to the final four weeks of the 18-month study period (approximately weeks 75-78), measured continuously using the Fitbit Charge 6 wearable activity monitor. Average daily step count will be calculated across four-week periods and analysed descriptively as a measure of engagement and sustainability in keeping with the feasibility aims of the study.	Baseline (weeks 0-4) to 18 months (weeks 75-78)
Feasibility of Study Delivery	Composite feasibility outcome assessed by: (1) proportion of eligible participants who consent to take part (recruitment rate); (2) proportion of randomised participants who complete the 18-month study period (retention); (3) adherence to the intervention, measured by app engagement metrics and Fitbit wear time; (4) completeness of remote and in-person assessment data; and (5) frequency and nature of adverse events (safety).	Throughout the 18-month study period, with summaries at 9 months and 18 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Moderate-to-Vigorous Physical Activity (MVPA) Intensity	Change in mean daily minutes spent at or above 64% of age-predicted maximum heart rate (HRmax), measured continuously via the Fitbit Charge 6 photoplethysmography sensor. Distribution of time across intensity bands will be described and the feasibility of capturing sustained heart-rate data over 18 months will be assessed. Analyses are exploratory only.	Baseline (weeks 0-4) to 9 months and 18 months
Cardiorespiratory Fitness: Estimated VO₂max	Feasibility of obtaining a remote estimate of aerobic fitness (VO₂max) via the Fitbit algorithm throughout the study period. Analyses will focus on completion rates, participant tolerance, and signal stability of remote VO₂max estimation. Resting heart rate and heart rate variability (HRV) will also be summarised as the average daily resting values to assess feasibility and stability of remote cardiovascular monitoring.	Continuously throughout the 18-month study period, with summaries at baseline, 9 months, and 18 months
Blood Pressure	Feasibility of repeated blood pressure measurement using standard sphygmomanometry, assessed at baseline and 18-month in-person visits. Supine and standing readings will be taken in accordance with American Autonomic Society recommendations to assess orthostatic hypotension. Collected for safety monitoring and feasibility assessment only; not used for clinical diagnosis.	Baseline and 18 months (in-person visits)
Remote Digital Motor Assessment: Roche Mobile Application V2	Feasibility of repeated remote motor task completion using the Roche Mobile Application V2 smartphone platform. Active tasks include finger tapping, shape drawing, reaction time, information processing, executive functioning, balance, gait, and upper limb performance, administered every 6 weeks throughout the study period. Feasibility assessed by number of data points received, proportion of expected submissions completed, and drop-off patterns across predefined 6-week windows from 0 to 78 weeks.	Every 6 weeks from randomisation to 18 months (approximately 13 assessment windows)
Structured Motor Examination: MDS-UPDRS Part III, Functional Gait Assessment, and Mini-BESTest	Feasibility of administering in-person structured motor assessments including the Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS Part III), the Functional Gait Assessment (FGA), and the Mini-Balance Evaluation Systems Test (Mini-BESTest), with and without cognitive dual-tasking. Examinations will be video recorded with participant consent to allow baseline and follow-up comparison. Videos are not used for clinical decision-making.	Baseline and 18 months (in-person visits)
Upper Limb Digital Motor Performance: BRAIN Test, Digital Finger Tapping, and Manus Neurodynamica Digital Pen	Feasibility of administering digital upper limb motor assessments at in-person visits, including: (1) the Bradykinesia Akinesia Incoordination (BRAIN) test, a validated computer-based keyboard tapping task; (2) the Digital Finger Tapping test; and (3) the Manus Neurodynamica digital pen, an AI-based handwriting and fine-motor assessment device recording kinematic and dynamic features of writing and drawing. These tools are included as exploratory assessments of upper limb motor function.	Baseline and 18 months (in-person visits)
Free-Living Mobility and Gait: Axivity AX6 Accelerometer	Feasibility of collecting continuous raw accelerometer data from a 6-axis inertial movement sensor (Axivity AX6) worn on the dominant wrist for 7-day bursts at specified time points. Data will provide wearable-derived digital mobility and gait metrics in free-living conditions. Analyses will assess completion rates, wear-time compliance, and data quality across assessment windows.	Baseline, 9 months, and 18 months (7-day wear bursts)
Oculomotor Assessment: NeuroClues Eye-Tracking	Feasibility of administering a standardised high-frequency binocular eye-tracking battery (NeuroClues) at in-person visits, including prosaccades, antisaccades, fixation, and pursuit tasks. Key endpoints include prosaccade latency (ms), antisaccade latency (ms), antisaccade error rate (%), fixation stability, and saccadic intrusions. Included as an exploratory assessment of oculomotor control only.	Baseline and 18 months (in-person visits)
Sleep Quality: Fitbit Sleep Metrics and Pittsburgh Sleep Quality Index (PSQI)	Feasibility of remote long-term sleep monitoring using the Fitbit Charge 6, capturing sleep onset latency (SOL), total sleep time (TST), sleep efficiency (SE), and duration of sleep stages (deep, light, REM, and awake). Complemented by the validated Pittsburgh Sleep Quality Index (PSQI) questionnaire administered at each assessment time point. Feasibility assessed by data completeness, wear-time adherence, and questionnaire completion rates.	Fitbit continuously throughout 18 months; PSQI at baseline, 9 months, and 18 months
Mood, Anxiety, and Psychological Wellbeing: HADS and Oxford Happiness Questionnaire	Feasibility of repeated administration of the Hospital Anxiety and Depression Scale (HADS) and the Oxford Happiness Questionnaire (OHQ), a 29-item self-report measure of subjective wellbeing. Feasibility assessed by questionnaire completion rates and missing data patterns. Mood and autonomic symptoms are also captured via MDS-UPDRS Part I at in-person visits.	Baseline, 9 months, and 18 months
Cognitive Function: Montreal Cognitive Assessment (MoCA)	Feasibility of administering the Montreal Cognitive Assessment (MoCA) at in-person visits to ensure participants can engage appropriately with study procedures and to assess the feasibility of repeated in-person cognitive testing in this population. Not used for clinical diagnosis or prediction.	Baseline (in-person visit)
Autonomic Symptoms: SCOPA-AUT	Feasibility of repeated administration of the validated Scales for Outcomes in Parkinson's Disease-Autonomic (SCOPA-AUT) questionnaire as a general autonomic function measure. Feasibility assessed by completion rates across repeated remote and in-person administrations.	Baseline, 9 months, and 18 months
Olfactory Function: UPSIT	Feasibility of repeated olfactory assessment using the 40-item University of Pennsylvania Smell Identification Test (UPSIT) at in-person visits. UPSIT scores will be recorded to assess the feasibility and stability of repeated olfactory testing across the study period. Results are not used for individual risk prediction or clinical diagnosis.	Baseline and 18 months (in-person visits)
Health-Related Quality of Life and Functional Status: WHOQOL-BREF and Lawton iADL Scale	Feasibility of administering the World Health Organisation Quality of Life assessment (WHOQOL-BREF) and Lawton's Instrumental Activities of Daily Living (iADL) scale at annual assessment time points. Feasibility assessed by completion rates, missing data patterns, and participant burden ratings.	Baseline and 18 months
Smartphone Application Usability: System Usability Scale (SUS)	Feasibility and acceptability of the Slow-SPEED smartphone application assessed using the System Usability Scale (SUS). Participant ratings will be used to evaluate usability and inform improvements to the user experience for a future definitive trial.	9 months and 18 months
Digital Engagement and App Usage	Quantitative assessment of participant interaction with the Slow-SPEED application, measured by total number of app opens across predefined time windows: baseline period (0-1 month), and post-randomisation periods of 1-6 months, 6-12 months, and 12-18 months. Reported separately by study arm.	Throughout the 18-month study period
Adherence to Weekly Step and Activity Goals	Compliance with the intervention assessed by: (1) proportion of participants achieving an increase in mean daily step count relative to baseline at 18 months, categorised as 0-25%, 26-50%, 51-75%, and 76-100% increase; (2) proportion achieving an increase in mean daily MVPA minutes relative to baseline, using the same categories; (3) total number of weekly step goals completed across the 18-month period; and (4) total number of weekly intensity goals completed across the 18-month period. Reported separately for both study arms.	Throughout the 18-month study period, with summaries at 6, 12, and 18 months
Participant Retention	Proportion of randomised participants remaining in the study without withdrawal, assessed at 6, 12, and 18 months following randomisation. Reported separately for the intervention and active control arms.	6 months, 12 months, and 18 months
Motivators and Barriers to Physical Activity Engagement	Feasibility of administering a self-designed questionnaire to explore participant-reported motivators and barriers to engagement with the physical activity programme. Responses will inform the design and participant support strategies for a future definitive trial.	Baseline and 18 months
Research Composite Score (RCS)	An exploratory composite research index aggregating standardised scores across four domains already collected within the study: Physical activity domain-average daily step count and mean daily MVPA minutes, derived continuously from the Fitbit Charge 6 Self-reported symptom domain-scores from HADS, PSQI, WHOQOL-BREF, SCOPA-AUT, and Lawton iADL scale Sensory domain-UPSIT olfactory score adjusted for age and sex Digital engagement domain-Fitbit wear time, Slow-SPEED app opens, and Roche Mobile Application V2 completion rates Domain scores will be standardised and combined descriptively to characterise overall patterns of engagement and function across the study period. The RCS is a research-only instrument. No individual-level scores or predictions will be generated, communicated to participants, or used for clinical decision-making. Results will be used solely to inform the design of a future definitive trial.	Baseline, 9 months, and 18 months

Collaborators and Investigators

• Sponsor: Queen Mary University of London
• Collaborators: Radboud University Medical Center
• Investigators: Principal Investigator: Alastair J Noyce, BMedSci, MBBS, MSc, MRCP, PhD, Centre for Preventive Neurology, Queen Mary University of London

Publications and helpful links

General Publications

• Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav. 1984 Mar;32(3):489-502. doi: 10.1016/0031-9384(84)90269-5.
• Brickwood KJ, Watson G, O'Brien J, Williams AD. Consumer-Based Wearable Activity Trackers Increase Physical Activity Participation: Systematic Review and Meta-Analysis. JMIR Mhealth Uhealth. 2019 Apr 12;7(4):e11819. doi: 10.2196/11819.
• Paluch AE, Bajpai S, Bassett DR, Carnethon MR, Ekelund U, Evenson KR, Galuska DA, Jefferis BJ, Kraus WE, Lee IM, Matthews CE, Omura JD, Patel AV, Pieper CF, Rees-Punia E, Dallmeier D, Klenk J, Whincup PH, Dooley EE, Pettee Gabriel K, Palta P, Pompeii LA, Chernofsky A, Larson MG, Vasan RS, Spartano N, Ballin M, Nordstrom P, Nordstrom A, Anderssen SA, Hansen BH, Cochrane JA, Dwyer T, Wang J, Ferrucci L, Liu F, Schrack J, Urbanek J, Saint-Maurice PF, Yamamoto N, Yoshitake Y, Newton RL Jr, Yang S, Shiroma EJ, Fulton JE; Steps for Health Collaborative. Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts. Lancet Public Health. 2022 Mar;7(3):e219-e228. doi: 10.1016/S2468-2667(21)00302-9.
• Patel ZM, Holbrook EH, Turner JH, Adappa ND, Albers MW, Altundag A, Appenzeller S, Costanzo RM, Croy I, Davis GE, Dehgani-Mobaraki P, Doty RL, Duffy VB, Goldstein BJ, Gudis DA, Haehner A, Higgins TS, Hopkins C, Huart C, Hummel T, Jitaroon K, Kern RC, Khanwalkar AR, Kobayashi M, Kondo K, Lane AP, Lechner M, Leopold DA, Levy JM, Marmura MJ, Mclelland L, Miwa T, Moberg PJ, Mueller CA, Nigwekar SU, O'Brien EK, Paunescu TG, Pellegrino R, Philpott C, Pinto JM, Reiter ER, Roalf DR, Rowan NR, Schlosser RJ, Schwob J, Seiden AM, Smith TL, Soler ZM, Sowerby L, Tan BK, Thamboo A, Wrobel B, Yan CH. International consensus statement on allergy and rhinology: Olfaction. Int Forum Allergy Rhinol. 2022 Apr;12(4):327-680. doi: 10.1002/alr.22929.
• Yuan Y, Chamberlin KW, Li C, Luo Z, Simonsick EM, Kucharska-Newton A, Chen H. Olfaction and Mobility in Older Adults. JAMA Otolaryngol Head Neck Surg. 2024 Mar 1;150(3):201-208. doi: 10.1001/jamaoto.2023.4375.
• Yeo BSY, Chan JH, Tan BKJ, Liu X, Tay L, Teo NWY, Charn TC. Olfactory Impairment and Frailty: A Systematic Review and Meta-Analysis. JAMA Otolaryngol Head Neck Surg. 2024 Sep 1;150(9):772-783. doi: 10.1001/jamaoto.2024.1854.
• Johnston W, Judice PB, Molina Garcia P, Muhlen JM, Lykke Skovgaard E, Stang J, Schumann M, Cheng S, Bloch W, Brond JC, Ekelund U, Grontved A, Caulfield B, Ortega FB, Sardinha LB. Recommendations for determining the validity of consumer wearable and smartphone step count: expert statement and checklist of the INTERLIVE network. Br J Sports Med. 2021 Jul;55(14):780-793. doi: 10.1136/bjsports-2020-103147. Epub 2020 Dec 24.
• Noyce AJ, R'Bibo L, Peress L, Bestwick JP, Adams-Carr KL, Mencacci NE, Hawkes CH, Masters JM, Wood N, Hardy J, Giovannoni G, Lees AJ, Schrag A. PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease. Mov Disord. 2017 Feb;32(2):219-226. doi: 10.1002/mds.26898. Epub 2017 Jan 16.
• Yuan Y, Li C, Luo Z, Simonsick EM, Shiroma EJ, Chen H. Olfaction and Physical Functioning in Older Adults: A Longitudinal Study. J Gerontol A Biol Sci Med Sci. 2022 Aug 12;77(8):1612-1619. doi: 10.1093/gerona/glab233.
• Oleszkiewicz A, Croy I, Hummel T. The impact of olfactory loss on quality of life: a 2025 review. Chem Senses. 2025 Jan 22;50:bjaf023. doi: 10.1093/chemse/bjaf023.
• Lipsmeier F, Taylor KI, Postuma RB, Volkova-Volkmar E, Kilchenmann T, Mollenhauer B, Bamdadian A, Popp WL, Cheng WY, Zhang YP, Wolf D, Schjodt-Eriksen J, Boulay A, Svoboda H, Zago W, Pagano G, Lindemann M. Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson's disease. Sci Rep. 2022 Jul 15;12(1):12081. doi: 10.1038/s41598-022-15874-4.
• Li R, Li Y, Wang L, Li L, Fu C, Hu D, Wei Q. Wearable Activity Tracker-Based Interventions for Physical Activity, Body Composition, and Physical Function Among Community-Dwelling Older Adults: Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Med Internet Res. 2025 Apr 3;27:e59507. doi: 10.2196/59507.

Helpful Links

• Slow-SPEED-UK participants will be identified via PREDICT-PD.
• Slow-SPEED UK participants will be identified via the The Smell & Taste Clinic ENT Department James Paget University Hospital NHS Foundation Trust via collaborator: Professor Carl Philpott, Gorleston, Great Yarmouth Norfolk, NR31 6LA
• Slow-SPEED International (including Slow-SPEED UK site) LinkedIn profile

Study record dates

Study Major Dates

• Study Start (Estimated): May 1, 2026
• Primary Completion (Estimated): October 31, 2027
• Study Completion (Estimated): October 31, 2027

Study Registration Dates

• First Submitted: July 22, 2024
• First Submitted That Met QC Criteria: September 13, 2024
• First Posted (Actual): September 19, 2024

Study Record Updates

• Last Update Posted (Actual): April 15, 2026
• Last Update Submitted That Met QC Criteria: April 10, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Physical activity; Smartphone application; Hyposmia; Olfactory dysfunction; Wearable technology; Digital health intervention; Feasibility randomized controlled trial
• Additional Relevant MeSH Terms: Neurologic Manifestations; Nervous System Diseases; Sensation Disorders; Olfaction Disorders; Pathological Conditions, Signs and Symptoms; Behavior; Signs and Symptoms; Anosmia; Motor Activity
• Other Study ID Numbers: 362207

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No